EMI (Encore Medical) Short-Term Debt: $1.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Encore Medical Short-Term Debt?

Encore Medical EMI Short-Term Debt is $1.51 Mil as of Dec. 2025.

Encore Medical's Short-Term Debt for the quarter that ended in Dec. 2025 was $1.51 Mil.

Encore Medical's quarterly Short-Term Debt increased from Jun. 2025 ($0.17 Mil) to Sep. 2025 ($0.22 Mil) and increased from Sep. 2025 ($0.22 Mil) to Dec. 2025 ($1.51 Mil).

Encore Medical's annual Short-Term Debt increased from Dec. 2023 ($0.05 Mil) to Dec. 2024 ($0.05 Mil) and increased from Dec. 2024 ($0.05 Mil) to Dec. 2025 ($1.51 Mil).

Encore Medical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Encore Medical Short-Term Debt Related Terms

Encore Medical Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Encore Medical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Short-Term Debt Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Short-Term Debt
0.05 0.05 1.51

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Short-Term Debt Get a 7-Day Free Trial 0.00 0.05 0.17 0.22 1.51
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $1.51 Mil mean?
Encore Medical (EMI) has a Short-Term Debt of $1.51 Mil as of Dec. 2025.
Is Encore Medical's Short-Term Debt too high?
Encore Medical's current Short-Term Debt is $1.51 Mil.
How does Encore Medical's Short-Term Debt compare to ?
Encore Medical's Short-Term Debt of $1.51 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Medical Devices & Instruments company?
A good Short-Term Debt depends on the Medical Devices & Instruments industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Encore Medical's current Short-Term Debt is $1.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Short-Term Debt of $1.51 Mil. The current Short-Term Debt is $1.51 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Encore Medical (EMI), the current Short-Term Debt is $1.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).